Transcode Therapeutics, Inc.

Name: Transcode Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

RNAZNasdaqCIK 1829635HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$6.8m, Q2 FY2026

Net income−$6.8m, Q2 FY2026

Transcode Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q3 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$m	3.3	3.4	1.8	3.1	1.2	3.6	2.2	2.6	3.2	5.5	5.1	3.7
Operating income	$m	(5.3)	(4.1)	(3.3)	(5.1)	(2.2)	(5.1)	(3.2)	(4.2)	(4.6)	(16.0)	(17.8)	(6.8)
Interest expense	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported
Income tax	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	not reported	not reported
Net income	$m	(5.3)	(4.1)	(3.3)	(5.2)	(2.3)	(5.9)	(12.1)	(4.3)	(4.9)	(13.4)	(17.8)	(6.8)
Diluted EPS	$ per share	(48.44)	not reported	(21.35)	(680.23)	(146.06)	not reported	(70.16)	(5.13)	(5.82)	not reported	(21.28)	(7.17)
Basic EPS	$ per share	(48.44)	not reported	(21.35)	(680.23)	(146.06)	not reported	(70.16)	(5.13)	(5.82)	not reported	(21.28)	(7.17)

Balance sheet

Cash and equivalents$8.4m, Q2 FY2026

Shareholders' equity−$27.7m, Q2 FY2026

Transcode Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q3 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	7.5	2.8	4.9	3.4	1.9	5.8	11.6	7.4	2.8	17.8	12.8	8.4
Current assets	$m	9.4	4.5	6.7	4.4	3.6	7.1	13.0	8.2	4.8	22.0	16.7	10.6
Total assets	$m	10.2	5.2	7.3	4.8	3.9	7.3	13.2	8.3	5.2	162	157	151
Current liabilities	$m	5.6	3.5	2.7	3.5	2.3	2.8	2.5	1.6	3.0	3.5	5.4	5.4
Total liabilities	$m	5.8	3.5	2.7	3.5	2.3	9.3	2.9	2.1	3.8	10.5	12.6	12.7
Shareholders' equity	$m	4.4	1.6	4.6	1.3	1.7	(2.0)	10.3	6.1	1.4	10.3	1.3	(27.7)

Cash flow

Operating cash flow−$5.4m, Q2 FY2026

Capital expenditure$500, Q4 FY2024

Transcode Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q3 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(3,506)	(5,663)	(3,937)	(2,340)	(3,913)	(3,146)	(3,097)	(4,194)	(4,083)	(8,142)	(4,978)	(5,402)
Capital expenditure	$k	4.6	0.0	3.8	4.6	12.9	0.5	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)957,191, Q2 FY2026

Transcode Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q3 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	649	18.6	30.5	109	156	7.6	15.9	172	834	834	917	957

Shares outstanding: 16.93m at Aug 10, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.